Elicio Therapeutics Ownership | Who Owns Elicio Therapeutics?

Elicio Therapeutics Ownership Summary

Elicio Therapeutics is owned by 12.29% institutional investors, 45.04% insiders, and 42.67% retail investors.

ELTX Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Elicio Therapeutics	12.29%	45.04%	42.67%
Sector	Healthcare Stocks	278.70%	10.61%	-189.31%
Industry	Biotech Stocks	63.84%	10.66%	25.50%

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	24	41.18%	1,591,744	250.55%	12	88.77%	17	325.00%	2	-66.67%
Dec 31, 2024	17	-5.56%	454,072	-7.61%	3	28.42%	4	-60.00%	6	500.00%
Sep 30, 2024	18	-5.26%	491,473	-24.23%	3	10.95%	10	-23.08%	1	-
Jun 30, 2024	19	5.56%	648,667	59.59%	5	36.72%	13	62.50%	1	-66.67%
Mar 31, 2024	18	-	406,457	22.10%	3	9.13%	8	14.29%	3	-25.00%

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 12, 2024	Chudnovsky Yekaterina		Buy	$20.00M
Jun 28, 2024	Venkatesan Jay	-	Buy	$250.00K
Jun 28, 2024	Venkatesan Jay	-	Buy	$500.00
Jun 28, 2024	Chudnovsky Yekaterina		Buy	$8.00M
Jun 28, 2024	Chudnovsky Yekaterina		Buy	$16.00K

Insider Transactions Trends

Date	Buy	Sell
2025 Q2	-	-
2025 Q1	-	-
2024 Q4	-	-
2024 Q3	1	-
2024 Q2	4	-

ELTX Ownership FAQ

Who Owns Elicio Therapeutics?

Elicio Therapeutics shareholders are primarily institutional investors at 12.29%, followed by 45.04% insiders and 42.67% retail investors. The average institutional ownership in Elicio Therapeutics's industry, Biotech Stocks , is 63.84%, which Elicio Therapeutics falls below.

Does Blackrock own Elicio Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Elicio Therapeutics.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools